Transient Inhibition of Transforming Growth Factor-beta1 in Human Diabetic CD34+ Cells Enhances Vascular Reparative Functions
Overview
Authors
Affiliations
Objective: Peripheral blood CD34(+) cells from diabetic patients demonstrate reduced vascular reparative function due to decreased proliferation and diminished migratory prowess, largely resulting from decreased nitric oxide (NO) bioavailability. The level of TGF-beta, a key factor that modulates stem cell quiescence, is increased in the serum of type 2 diabetic patients. We asked whether transient TGF-beta1 inhibition in CD34(+) cells would improve their reparative ability.
Research Design And Methods: To inhibit TGF-beta1 protein expression, CD34(+) cells were treated ex vivo with antisense phosphorodiamidate morpholino oligomers (TGF-beta1-PMOs) and analyzed for cell surface CXCR4 expression, cell survival in the absence of added growth factors, SDF-1-induced migration, NO release, and in vivo retinal vascular reparative ability.
Results: TGF-beta1-PMO treatment of diabetic CD34(+) cells resulted in increased expression of CXCR4, enhanced survival in the absence of growth factors, and increased migration and NO release as compared with cells treated with control PMO. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34(+) cells to injured acellular retinal capillaries was greater after TGF-beta1-PMO treatment compared with control PMO-treated cells.
Conclusions: Transient inhibition of TGF-beta1 may represent a promising therapeutic strategy for restoring the reparative capacity of dysfunctional diabetic CD34(+) cells.
Danila A, Ghenciu L, Stoicescu E, Bolintineanu S, Iacob R, Sandesc M Biomedicines. 2024; 12(4).
PMID: 38672103 PMC: 11047946. DOI: 10.3390/biomedicines12040747.
Jahan J, Joshi S, Oca I, Toelle A, Lopez-Yang C, Chacon C Biochem Pharmacol. 2024; 222:116109.
PMID: 38458330 PMC: 11007670. DOI: 10.1016/j.bcp.2024.116109.
Stem cells and diabetic retinopathy: From models to treatment.
Saha B, Roy A, Beltramo E, Sahoo O Mol Biol Rep. 2023; 50(5):4517-4526.
PMID: 36842153 DOI: 10.1007/s11033-023-08337-0.
Liang Z, Wang Y, Li J, Yang W, Tu Y, Zhang Y Int J Ophthalmol. 2022; 15(10):1577-1585.
PMID: 36262844 PMC: 9522570. DOI: 10.18240/ijo.2022.10.03.
Jahan J, Monte de Oca I, Meissner B, Joshi S, Maghrabi A, Quiroz-Olvera J Eur J Pharmacol. 2022; 920:174842.
PMID: 35217004 PMC: 8967481. DOI: 10.1016/j.ejphar.2022.174842.